ConductScreen

Regulatory Evidence

NAM-vs-Animal Concordance Dashboard

How ConductScreen features map to OECD TG 426 developmental neurotoxicity endpoints, with published evidence for each mapping.

7

Features Mapped

3

Strong Concordances

4

Substance Classes Covered

Evidence:
Module:

Area / Equivalent Diameter

MorphologyStrongPhase 1 Validated

Effect Size

|r| = 0.52–1.00

ConductScreen

Morphology

Phase 1 — Validated

OECD TG 426

Cross-sectional area of brain regions

Sections 43–46

Organoid area reflects tissue growth capacity; ethanol-exposed rat pups show reduced cortical area (Maier et al., 1999); organoid area is reduced by ethanol (Adams et al., 2023).

EthanolVPAMethadone3/9 classes

Solidity

MorphologyStrongPhase 1 Validated

Effect Size

|r| = 0.57–0.67

ConductScreen

Morphology

Phase 1 — Validated

OECD TG 426

Tissue integrity / neuropathological assessment

Section 43

Solidity measures tissue compactness; decreased solidity indicates disintegration/loosening, analogous to tissue degeneration scored in TG 426 neuropathology.

EthanolVPAMethadone3/9 classes

Contrast / Texture Homogeneity

MorphologyModeratePhase 1 Validated

Effect Size

|r| = 0.62–0.79

ConductScreen

Morphology

Phase 1 — Validated

OECD TG 426

Cellular architecture / organization

Section 45

Texture features capture local cellular organization; increased contrast / decreased homogeneity indicates disrupted layering, analogous to disorganized cortical architecture in TG 426 histopathology.

EthanolVPAMethadone3/9 classes

Std Intensity / Intensity Range

MorphologyModeratePhase 1 Validated

Effect Size

|r| = 0.93

ConductScreen

Morphology

Phase 1 — Validated

OECD TG 426

Differentiation markers / heterogeneity

Sections 44–45

Intensity heterogeneity reflects differentiation state variation within organoid; analogous to altered marker expression patterns in developing rat brain.

VPAMethadoneEthanol3/9 classes

Growth Velocity / Doubling Time

TemporalStrongPhase 1 Validated

Effect Size

14.4x / 10.9x / 7.5x fold-change

ConductScreen

Temporal

Phase 1 — Prototype

OECD TG 426

Brain weight / body weight ratio

Sections 41–42

Organoid growth rate is the in vitro analog of brain growth; dose-dependent growth arrest (Yao 2020, methadone) parallels reduced brain weight in exposed rat pups.

EthanolVPAMethadone3/9 classes

Boundary Roughness / Fractal Dimension

BoundaryEmerging

Effect Size

Proof-of-concept

ConductScreen

Boundary

Phase 2 — Planned

OECD TG 426

Neurite outgrowth / dendritic arborization

Sections 45–46

Boundary roughness in brightfield is a proxy for neurite-producing organoids; smooth boundaries indicate compact organoids with less outgrowth. Multiple substance classes affect neurite coverage in published review literature.

EthanolMethadoneCocaine3/9 classes

Burst Rate / Synchrony Index

ElectrophysiologyEmerging

Effect Size

Phase 2 planned

ConductScreen

Electrophysiology

Phase 2 — Planned

OECD TG 426

Functional neuronal activity / behavioral endpoints

Sections 47–51

MEA electrophysiology in organoids measures functional network activity; substance-disrupted network formation produces altered burst patterns analogous to behavioral deficits in exposed rat pups.

Multiple substance classes1/9 classes

Full Concordance Mapping

Tabular overview of all ConductScreen-to-TG 426 mappings

FeatureModuleTG 426 EndpointStrengthSubstancesEffect Size
Area / Equivalent DiameterMorphologyCross-sectional area of brain regionsStrong3/9|r| = 0.52–1.00
SolidityMorphologyTissue integrity / neuropathological assessmentStrong3/9|r| = 0.57–0.67
Contrast / Texture HomogeneityMorphologyCellular architecture / organizationModerate3/9|r| = 0.62–0.79
Std Intensity / Intensity RangeMorphologyDifferentiation markers / heterogeneityModerate3/9|r| = 0.93
Growth Velocity / Doubling TimeTemporalBrain weight / body weight ratioStrong3/914.4x / 10.9x / 7.5x fold-change
Boundary Roughness / Fractal DimensionBoundaryNeurite outgrowth / dendritic arborizationEmerging3/9Proof-of-concept
Burst Rate / Synchrony IndexElectrophysiologyFunctional neuronal activity / behavioral endpointsEmerging1/9Phase 2 planned